Genetically encoded fluorescent antibodies are desirable for many applications in biotechnology and proteomics. However, the efficient production of single chain antibodies fused to fluorescent proteins like green fluorescent protein is still a major challenge. This is due to the opposite redox requirements of recombinant antibodies and fluorescent proteins for proper folding. To overcome this obstacle, we designed a novel strategy to directly select functional fluorescent antibodies (fluobodies) engineered for efficient cytosolic expression in Escherichia coli, starting from a llama heavy chain antibody (VHH) library. We used this strategy to produce several VHH fluobodies directed against microtubules. After biochemical characterization in vitro, we used a selected fluobody as a convenient biomarker of the microtubule cytoskeleton in eukaryotic cells and engineered its properties. This work provides a reliable approach for the production of fluobodies in wild-type E. coli and furthermore suggests that fusions of recombinant VHH with other cytosolic proteins are now possible, creating new opportunities for biotechnology and biomedical research.
Antibodies can bind antigens with high affinity and high specificity. Their binding domains can be artificially expressed as recombinant single polypeptide chains. This allows the construction of recombinant antibody libraries in bacteria from which antibodies with desired binding properties can be selected (1) . Most common are single chain Fv (scFv) 3 antibody fragments, in which the variable domains of the heavy and light chains of IgG molecules are held together by a short linker. In addition, several other single domain scaffolds are emerging now (2, 3) . One promising alternative to the scFv fragments are the variable domains of heavy chain antibodies from Camelidae (VHH). They are naturally devoid of light chains and contain the full antigen binding capacity in a single polypeptide chain (4, 5) . VHH molecules represent the smallest known natural antigen-binding domain (6) .
To produce antibodies directed against essential eukaryotic proteins, it can be advantageous to perform their selection and production in bacteria to avoid toxicity effects and to obtain large amount of purified protein. Furthermore, the availability of recombinant fluorescent antibodies would simplify traditional immunoassays and be a major advance for modern fluorescence imaging techniques, e.g. in the emerging field of biosensors of protein activities. However, the efficient production of direct fusions between recombinant antibodies and fluorescent proteins in Escherichia coli has been a major challenge. Because recombinant antibodies contain disulfide bonds, they require an oxidizing environment for correct folding and are therefore expressed either in the secretory pathway of eukaryotic cells or more commonly in the periplasm of bacteria (7, 8) . In contrast, fluorescent proteins like green fluorescent protein (GFP) fold correctly in the cytosol but not in the periplasm of E. coli (9) . For example, scFv-GFP fusions have been produced only in a few cases in E. coli and not surprisingly only at very low yields of active protein (10 -14) . In exceptional cases, antibody scaffolds are stable without the formation of disulfide bonds (15, 16) . This is probably a prerequisite for the reported stable folding of some antibody fragment-GFP fusions expressed as intrabodies in cultured eukaryotic cells (17) (18) (19) . A general solution to the folding problem of fusions of recombinant antibodies and fluorescent proteins is still lacking, however.
In this study, we report an efficient solution to this folding problem for a subclass of recombinant antibodies that are especially suited for the generation of fluorescent antibodies. We designed and tested a direct selection strategy based on the coexpression of a chaperone to obtain fluorescent single domain antibodies engineered for efficient expression in the cytosol of wild-type E. coli. We used this novel approach for the selection of fluorescent antibodies directed against microtubules. We demonstrate proper folding and high specificity and affinity of a selected microtubule biomarker.
EXPERIMENTAL PROCEDURES
Plasmid Construction-For the cytosolic expression of fluorescent VHH, the fluobody vector pAOD-GFP was constructed by inserting PCR-amplified monomeric GFP (upstream primer, 5Ј-GGACTTGGCGGCCGCAGCGGTTCTGGTCCGGGCG-GTTCACCGGTGGGTATGAGCGTGAGCAAGGGCGAG-GAG-3Ј; and downstream primer, 5Ј-CTGAACCGCTCCAA-CTTGGATCCTTACTTAACTATTAGGTACCATCTGAG-* This work was supported in part by European Union Research Training Network MRTN-CT-2004-512348. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. □ S The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. 1 and TACTTGTACAG-3Ј) (a kind gift from Jennifer LippincottSchwartz) between the NotI and BamHI sites of plasmid pETM-82 (a kind gift from Gunter Stier, European Molecular Biology Laboratory). The generated plasmid encodes the leaderless disulfide bond isomerase DsbC (disulfide bond oxidoreductase and isomerase C), followed by a His 6 tag, a tobacco etch virus protease site, and monomeric GFP. VHH genes can be inserted between the tobacco etch virus site and monomeric GFP using the NcoI and NotI restriction sites. For analysis of the folding of VHH Tub1, the pAOD-Tub1 vector was generated by removing monomeric GFP from pAODTub1-GFP using the NotI and Acc65I sites. The plasmid was religated after removal of the overhang using mung bean nuclease. pAOZ-Tub1 and the pAOZ-Tub1-GFP were created by replacing DsbC in pAOD-Tub1 and pAOD-Tub1-GFP with the Z tag from the pETM-Z vector (a kind gift from Günter Stier) using XbaI and NcoI restriction sites. For periplasmic expression in E. coli XL1-Blue cells (20) , VHH Tub1 was recloned into the expression vector pHEN6 (21) using the restriction enzymes NcoI and NotI.
To generate a bivalent Tub1 antibody, PCR-amplified Tub1 (upstream primer, 5Ј-CTCGCGGCCCAGCCGGCCATGGC-GGATGTGCAGCTTCAGGCGTCTGGG-3Ј; and downstream primer, 5Ј-GCATTGGTTCTGCAGTTGCACATCT-GACGGCGGGGTGGACGGAGACGGCCGCGGCGGGGT-AGACGGGCCCGATGAGGAGACGGTGACCTGG-3Ј) was inserted between the NcoI and PstI sites of pAOD-Tub1-GFP. The two Tub1 VHH domains are separated by a modified hinge domain of IgA in this newly created pAODbivTub1-GFP construct.
Immunization and Library Construction-A llama (Eurogentec) was injected six times subcutaneously at weekly intervals with 500 g of a mixture of highly purified pig brain tubulin and partially purified Xenopus laevis egg extract tubulin (22) . Sixty days after the start of the immunization, peripheral blood lymphocytes were isolated from 300 ml of blood (Lymphoprep, Axis-Shield). The RNA was extracted from the lymphocytes using the RNA II purification kit (Macherey-Nagel). mRNA was isolated using oligo(dT) magnetic beads (Dynal Biotech), and the cDNA was prepared using SuperScript III reverse transcriptase (Invitrogen). Gene fragments encoding the variable and CH2 domains were amplified by PCR using primers 5Ј-GTCCTGGCTGCTCTTCTACAAGG-3Ј and 5Ј-GGTACGT-GCTGTTGAACTGTTCC-3Ј, which anneal at the leader sequence and at the CH2 exon of the heavy chains of all llama immunoglobulins, respectively. The 600-bp fragments (VHH-CH2 without the CH1 exon) were eluted from an agarose gel after separation from the 900-bp fragments (VH-CH1-CH2 exons). Because all VHH molecules belong to the same family (family III), they could be amplified by one additional PCR with primers 5Ј-AACATGCCATGACTCGCGGCTCAACCGGCCATGGCTG-AKGTBCAGCTGCAGGCGTCTGGRGGAGG-3Ј and 5Ј-ATT-ATTATTCAGATTATTAGTGCGGCCGCGTGAGGAGACG-GTGACCWGGGTCC-3Ј, which anneal at the framework 1 and 4 regions, respectively. The final PCR fragments were ligated into the modified phagemid vector pHEN4 (23) using the upstream restriction site NcoI or PstI and the downstream restriction site NotI. Ligated material was transformed into E. coli TG1 cells. This phagemid library was stored at Ϫ80°C in LB medium supplemented with glycerol (50% final concentration).
Selection by Phage Display-To display VHH on phages, the phagemid library was expressed after infection with M13K07⌬pIII hyperphages (24) (Progen). VHH molecules recognizing microtubules were enriched by three consecutive rounds of in vitro selection. Selection was achieved by co-sedimentation of phages with microtubules (stabilized by the nonhydrolyzable GTP analog GMP-CPP (25)) at 30,000 ϫ g, followed by resuspension of phages after depolymerization of microtubules in cold water. Phage particles were finally used to infect exponentially growing E. coli TG1 cells.
Selection of Fluobodies-To directly screen for functional fluobodies, after the third round of panning, the selected colonies were pooled; phagemid DNA was extracted; and the VHH inserts were cloned NcoI-NotI in the pAOD-GFP vector, thus creating the fluobody library. Several hundred colonies were picked to isolate individual plasmids using a 96-well miniprep kit (Macherey-Nagel). The plasmids were individually transformed into E. coli BL21 Star-pRARE cells and spotted on plates. Single colonies were grown in 96-well plates in LB medium supplemented with 0.1% glucose and antibiotics until A 600 ϭ 0.6 -0.8 was reached. Fluobody expression was then induced with 500 M isopropyl ␤-D-thiogalactopyranoside for 12 h at 18°C. After centrifugation, the cell pellets were lysed and centrifuged again. The cleared lysate was directly used at a 1:100 dilution in immunofluorescence (see below) on normal rat kidney (NRK) cells cultured in glass-bottom 96-well plates. Automated acquisition of cell images was performed using a Zeiss Cell Observer microscope with a ϫ40 objective and Zeiss AxioVision software.
Expression and Purification of Recombinant Antibodies-For the purification of fluobodies, the plasmid constructs were transformed into E. coli BL21 Star-pRARE cells and induced as described above. Cell lysates were cleared and loaded onto a Proteino/Ni-TED resin affinity column (Macherey-Nagel). The eluted fraction was dialyzed, and if necessary, cleavage with a His 6 -tagged tobacco etch virus protease (European Molecular Biology Laboratory) was performed overnight at 4°C. The tobacco etch virus protease was removed together with the cleaved DsbC-His 6 tag by chromatography using a Talon metal affinity matrix (Clontech), and the purity of the protein was analyzed by SDS-PAGE. Tub1 cut_DsbC and DsbC-bivTub1-GFP were further purified using HiTrap SP and Superose 6 columns (Amersham Biosciences), respectively. The final yield of purified VHH was determined using the theoretical extinction coefficient for the absorption at 280 nm. CD spectra were measured with a Jasco Labor spectropolarimeter.
Immunofluorescence-NRK cells (American Type Culture Collection) were cultured on glass coverslips under standard conditions and fixed using a protocol for preservation of cytoskeletal structures (26) . Fixed cells were incubated with fluorescent VHH (20 -500 nM) or with periplasmically expressed VHH-His 6 (100 nM) for 1 h. For indirect immunofluorescence, an anti-pentahistidine monoclonal antibody (1:500; Qiagen Inc.) or a rabbit anti-␣-tubulin polyclonal antibody (1:300; Abcam) was used, followed by an Alexa 488-labeled anti-mouse or Alexa 595-or Alexa 488-labeled anti-rabbit secondary antibody (1:800; Molecular Probes). DNA was visualized by 4Ј,6-diamidino-2-phenylindole staining (0.02 g/ml). Coverslips were mounted with Dako mounting medium. Images were taken with a Zeiss Cell Observer microscope with a ϫ63 oil objective using AxioVision software.
In Vitro Microtubule Binding Assay-Gel-filtered fluobodies were precentrifuged at 85,000 rpm and then incubated at a concentration of 500 nM for 10 min with microtubules (5 M tubulin) in BRB80 (80 mM PIPES (pH 6.8), 1 mM MgCl 2 , and 1 mM EGTA) supplemented with 40 M Taxol, 10% glycerol, and 150 mM NaCl. The mixture was ultracentrifuged at 40,000 rpm for 10 min. Co-sedimentation was assessed by analyzing equal volumes of resuspended pellet and supernatant by SDS-PAGE and Coomassie Brilliant Blue staining.
For K d measurements, 2, 6, or 20 nM gel-filtrated and precentrifuged monovalent or bivalent VHH-GFP was mixed with 0.1 nM to 1 M microtubules in the presence of 1 M ␤-casein (Sigma). After ultracentrifugation for 5 min at 85,000 rpm, the fluorescence of unbound fluobody in the supernatant and of microtubule-bound fluobody in the dissolved pellet was measured using a Safire 2 TM spectrofluorometer (Tecan). Concentrations were calculated from the fluorescence signals using a calibration curve. The concentrations of free binding sites on the microtubules were obtained as the difference between the total microtubule concentration in the experiment and the measured concentration of bound fluobodies. A hyperbolic fit (F ϭ F max ⅐M/ (K d ϩ M) ) to the concentration of microtubule-bound fluobodies (F) as a function of the concentration of free binding sites on microtubules (M) provided the dissociation constant (K d ).
In Vitro Microtubule Bundling Assay-A solution of 50 nM gelfiltrated fluobodies was precentrifuged at 70,000 rpm and then incubated for 10 min with tetramethylrhodamine-labeled microtubules in BRB80 supplemented with 150 mM NaCl and 20 M Taxol. A sample of the mixture was directly observed between slide and coverslip by fluorescence microscopy (see above).
RESULTS AND DISCUSSION
We developed a direct screen for correctly folded and functional fluorescent antibodies starting from a library of recombinant antibody genes. Llama VHH was chosen as the antibody scaffold because llama VHH often has only one disulfide bond, whereas camel VHH and scFv fragments usually have two disulfide bonds that are required for their stability. Because our strategy is based on the cytosolic expression of VHH-GFP fusions, it was important to increase the probability of disulfide bond formation of VHH in the cytosol of bacteria without interfering with the GFP folding. Therefore, we first tested whether a method originally developed for improved disulfide bond formation of scFv molecules expressed in the cytosol of bacteria (29, 30) could be adapted for VHH-GFP.
To this end, we fused the leaderless disulfide bond isomerase DsbC, which is usually involved in disulfide bond maturation in the periplasm (31, 32) , to the N terminus of the test VHH molecule Re3, directed against the small GTPase Ran (33) , which also carried a C-terminal GFP extension. This construct could be expressed in the cytosol of the standard E. coli strain BL21(DE3) with a high yield (supplemental Fig. 1A) . We furthermore showed that VHH was functional using a binding assay (supplemental Fig. 1B ) and that the GFP fluorophore had formed using fluorescence spectroscopy (supplemental Fig.  1C ). We did not succeed in expressing VHH-GFP without the DsbC tag in a functional and fluorescent form in either the cytosol or the periplasm of various E. coli strains. These results suggest that the leaderless DsbC tag might also promote the efficient production of other functional recombinant VHH-GFP antibodies in the bacterial cytosol.
To demonstrate that fluobodies can be produced using a systematic approach, we decided to generate recombinant fluorescent antibodies that recognize microtubules and that can be used, for example, as convenient biomarkers of the eukaryotic cytoskeleton. To this end, we first produced a phagemid library containing VHH genes from lymphocytes of a llama that was immunized with tubulin. The size of the library was assessed by measuring the number of initial transformants, which was Ͼ10
7
. The complexity of the library was tested by sequencing 50 randomly picked clones (23) that were all found to be different. This indicates that the library was diverse. The procedure for the subsequent selection of fluorescent microtubule binders from this library consisted of two consecutive steps (Fig. 1A) .
Step 1 involved conventional phage display (biopanning) (34) to enrich for binders of microtubules in vitro and to reduce the size of the library for the next step. No co-selection for certain folding and fluorescence properties of VHH takes place here. The VHH folds in the bacterial periplasm without GFP while being fused to a surface protein of the phage.
Step 2 involves a novel direct immunofluorescence screen of fixed eukaryotic cells stained with bacterial lysates of a sublibrary expressing DsbC-VHH-GFP fusions in the cytosol. This second step co-selects in a very timeefficient manner for both specific antigen binding of VHH and generation of the fluorophore of GFP. Both requirements are fulfilled only if the VHH-GFP fusion folds efficiently in the cytosol.
The transition from the first biopanning by conventional phage display (35) to the second screen using direct immunofluorescence was made possible by subcloning the polyclonal pool of the VHH DNA from the selected phagemids after the last round of biopanning into a vector for cytosolic fluobody expression. This step generated a sublibrary with a pool of DsbC-VHH-GFP fusions, which was already enriched for tubulin binders by the previous biopanning. Several hundred individual clones of this fluobody sublibrary were then grown in liquid culture in 96-well plates. After cytosolic expression of the fluobodies, clarified cell lysates were used for the direct immunofluorescence screen of fixed NRK cells that were also grown in 96-well plates (Fig. 1B) . Automatic fluorescence imaging of the fluobody-stained NRK cells allowed the rapid identification of those clones that could be efficiently expressed in a functional form and that selectively bound microtubules in the presence of other cellular proteins. Of the nine identified clones, six differed in sequence (Fig. 1C) . All six fluobodies could be expressed and purified to further analyze their ability to label the microtubule cytoskeleton in NRK cells. In conclusion, our screen allowed the fast identification of the first anti-tubulin fluorescent antibodies produced in E. coli.
The fluobody clone (Tub1) giving the best staining of the microtubule cytoskeleton in direct immunofluorescence (Fig.  1D ) was selected for further characterization. First, we showed by fluorescence spectroscopy that the GFP fluorescence was not impaired by the presence of DsbC during cytosolic expression ( Fig. 2A) , confirming the result with the test VHH molecule Re3 (see above).
Next, we determined the secondary structure of the Tub1 VHH domain by CD spectroscopy (36) using constructs lacking C-terminal GFP. A DsbC-Tub1 fusion was expressed in the bacterial cytosol, and the structure of only the VHH domain was analyzed after proteolytic removal of the DsbC tag (producing Tub1 cut_DsbC ). The CD spectrum was characteristic for the native ␤-strand fold of VHH and indistinguishable from purified Tub1 expressed in the periplasm without DsbC ( peri Tub1) (Fig. 2B) . We also expressed in the cytosol a Z-Tub1 fusion as a control, in which the DsbC domain was replaced by the commonly used Z tag (a domain from Staphylococcus aureus protein A). Our aim was to determine whether a tag that can improve solubility but that has no disulfide oxidoreductase and isomerase activity could promote correct Tub1 folding in the cytosol. Although Z-Tub1 was as soluble as DsbC-Tub1 (supplemental Table 1 ), after removal of the Z tag, the purified VHH domain (Tub1 cut_Z ) was partially insoluble, and the soluble fraction showed a significant degree of random coil structure (Fig. 2B ). This indicates that the enzymatic activity of DsbC is required for the correct folding of Tub1 in the bacterial cytosol.
This conclusion was supported by two additional experiments comparing the binding properties of different Tub1 constructs. First, in a biochemical antigen binding assay, Tub1 cut_DsbC and peri Tub1, but not Tub1 cut_Z , co-sedimented with microtubules in vitro (data not shown). Second, in contrast to DsbC-Tub1-GFP, a fluorescent Z-Tub1-GFP construct ( Fig. 2A ) expressed in the cytoplasm did not label microtubules upon direct immunofluorescence of fixed NRK cells (Fig. 2C) , most likely because the VHH domain was not folded in this construct. In contrast and as expected, peri Tub1 specifically labeled microtubules upon indirect immunofluorescence using a secondary detection antibody (Fig. 2C) .
To test the specificity of Tub1 for microtubules by comparison with the control VHH Re3, purified Tub1-GFP was produced with a yield of 28 mg of purified protein/ liter of bacterial culture. First, we showed by SDS gel electrophoresis that the Tub1 fluobody co-sedimented with microtubules in vitro, in contrast to the Re3 fluobody, which did not bind to microtubules (Fig. 3B) . Similarly, Tub1-GFP, but not the control fluobody, co-localized to micro- tubules in NRK cells with the rabbit anti-␣-tubulin polyclonal antibody (Fig. 3A) . Interestingly, the labeling by direct immunofluorescence with Tub1-GFP (Figs. 1D, 2C , and 3A) appeared generally slightly more confined along the contour of the microtubules than the labeling by indirect immunofluorescence used for the secondary detection of peri Tub1 (Fig. 2C) or of the anti-␣-tubulin polyclonal antibody (Fig. 3A) . Taken together, these results confirm that the Tub1-GFP fluobody is specific for microtubules while offering advantages because of its high yield of production, ease of use, and the potential to be further engineered, e.g. by exchanging GFP with another fluorescent protein.
Finally, we tested whether we could engineer the properties of the Tub1-GFP fluobody by transforming it from a monovalent to a bivalent antibody. We constructed a tandem repetition of the Tub1 VHH domain separated by a linker. The bivalent DsbC-bivTub1-GFP fluobody could also be expressed in the bacterial cytosol (Fig. 3C ), but at lower yields compared with the monovalent version. To compare the affinities of the bivalent and monovalent fluobodies, we measured binding curves in vitro by co-sedimentation with microtubules, a simple method commonly used for microtubule-associated proteins (37), using directly the GFP fluorescence of the fluobodies as a readout. As expected, the affinity of the bivalent antibody was higher than that of the monovalent fluobody (Fig. 3D) . The dissociation constants of the monovalent and bivalent fluobodies (K d ϭ 31.2 Ϯ 3.2 and 2.4 Ϯ 0.3 nM, respectively) were in the range of those reported for other mono-or bivalent VHH molecules (38 -40) . The surprisingly low increase of affinity due to bivalency could be a consequence of steric constraints imposed on the VHH molecule when also the second domain of bivalent VHH binds to the rigid structure as a microtubule.
We could furthermore show by fluorescence microscopy with rhodamine-labeled microtubules polymerized in vitro that the affinity increase of the bivalent fluobody was correlated with its transformation into an artificial microtubule crosslinking molecule (Fig. 3E) . Bivalent bivTub1-GFP bound along microtubules and organized them into large bundles, whereas monovalent Tub1-GFP co-localized only with microtubules, but did not bundle them significantly. The VHH Re3-GFP control did not bind to microtubules, as expected (see also above). These results indicate that both VHH domains are functional in the purified bivalent fluobody and that they provide a nice example for the possibility to tailor the properties of recombinant antibodies to create molecules with novel functionalities.
In this study, we have demonstrated that llama single domain antibodies with single disulfide bonds fold correctly and can be produced very efficiently in the cytosol of bacteria. On the basis of this solution to the folding problem of recombinant antibodies in a reducing environment, we developed a method for the efficient production of genetically encoded fluorescent antibodies using llama VHH domains as a scaffold. Coexpression of fluorescent proteins and recombinant antibodies has so far been a major challenge, preventing the use of recombinant antibodies routinely as biosensors of, for example, protein activities, taking advantage of modern fluorescence imaging techniques. Because our method can probably also be used for the coexpression of recombinant VHH antibodies with other cytosolic proteins, it extends the repertoire of functionalities that can be engineered with recombinant antibodies. The possibility to tailor their properties at will promises to open new lines of research in the fields of biomarkers, biosensors, and nanobiotechnology.
